Terms: = Lymphoma AND BCL10, CIPER, 8915, ENSG00000142867, c-E10, CARMEN, mE10, CLAP
446 results:
1. Naturally occurring T cell mutations enhance engineered T cell therapies.
Garcia J; Daniels J; Lee Y; Zhu I; Cheng K; Liu Q; Goodman D; Burnett C; Law C; Thienpont C; Alavi J; Azimi C; Montgomery G; Roybal KT; Choi J
Nature; 2024 Feb; 626(7999):626-634. PubMed ID: 38326614
[TBL] [Abstract] [Full Text] [Related]
2. FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling.
Kanaoka D; Yamada M; Yokoyama H; Nishino S; Kunimura N; Satoyoshi H; Wakabayashi S; Urabe K; Ishii T; Nakanishi M
Cancer Res Commun; 2024 Feb; 4(2):312-327. PubMed ID: 38265263
[TBL] [Abstract] [Full Text] [Related]
3. In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma.
Sezer A; Mahmutović L; Akçeşme B
Med Oncol; 2023 Dec; 41(1):37. PubMed ID: 38155268
[TBL] [Abstract] [Full Text] [Related]
4. Inherited Human bcl10 Deficiencies.
Alsaidalani AA; García-Solís B; Bukhari E; Van Den Rym A; López-Collazo E; Sánchez-Ramón S; Corvillo F; López-Lera A; de Andrés A; Martínez-Barricarte R; Perez de Diego R
J Clin Immunol; 2023 Dec; 44(1):13. PubMed ID: 38129623
[TBL] [Abstract] [Full Text] [Related]
5. Chimeric and mutant CARD9 constructs enable analyses of conserved and diverged autoinhibition mechanisms in the CARD-CC protein family.
Staal J; Driege Y; Van Gaever F; Steels J; Beyaert R
FEBS J; 2024 Mar; 291(6):1220-1245. PubMed ID: 38098267
[TBL] [Abstract] [Full Text] [Related]
6. Regulatory roles of CARD9-bcl10-Rac1 (CBR) signalome in islet β-cell function in health and metabolic stress: Is there room for MALT1?
Kowluru A
Biochem Pharmacol; 2023 Dec; 218():115889. PubMed ID: 37991197
[TBL] [Abstract] [Full Text] [Related]
7. Primary Cutaneous Follicle Center lymphoma of the Eyelid in a Young Man.
Cárdenas-Belaunzarán J; Sánchez Castro OE; Mendoza Torres ML; Cuevas Martínez JL
Ophthalmic Plast Reconstr Surg; 2023 Nov-Dec 01; 39(6):e184-e186. PubMed ID: 37338339
[TBL] [Abstract] [Full Text] [Related]
8. Function and targeting of MALT1 paracaspase in cancer.
O'Neill TJ; Tofaute MJ; Krappmann D
Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
[TBL] [Abstract] [Full Text] [Related]
9. Dimethyl Fumarate Suppresses the Proliferation of HTLV-1-infected T Cells by Inhibiting CBM Complex-triggered NF-B Signaling.
Sato T; Maeta T; Ito S
Anticancer Res; 2023 May; 43(5):1901-1908. PubMed ID: 37097671
[TBL] [Abstract] [Full Text] [Related]
10. CARMA3: A potential therapeutic target in non-cancer diseases.
Gui Z; Zhang Y; Zhang A; Xia W; Jia Z
Front Immunol; 2022; 13():1057980. PubMed ID: 36618379
[TBL] [Abstract] [Full Text] [Related]
11. Assignment of IVL-Methyl side chain of the ligand-free monomeric human MALT1 paracaspase-IgL
Han X; Levkovets M; Lesovoy D; Sun R; Wallerstein J; Sandalova T; Agback T; Achour A; Agback P; Orekhov VY
Biomol NMR Assign; 2022 Oct; 16(2):363-371. PubMed ID: 36094731
[TBL] [Abstract] [Full Text] [Related]
12. The role of the CBM complex in allergic inflammation and disease.
DeVore SB; Khurana Hershey GK
J Allergy Clin Immunol; 2022 Nov; 150(5):1011-1030. PubMed ID: 35981904
[TBL] [Abstract] [Full Text] [Related]
13. bcl10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine.
Phelan JD; Oellerich T
Cancer Discov; 2022 Aug; 12(8):1844-1846. PubMed ID: 35929131
[TBL] [Abstract] [Full Text] [Related]
14. bcl10 loss-of-function novel mutation leading to atypical severe combined immunodeficiency.
Al-Tamemi S; Alhinai Z; Al-Rahbi N; Al-Abdawani R; Al-Yazidi L; Al-Shekaili J; Al-Kindi M; Al-Maawali A
Clin Immunol; 2022 Aug; 241():109067. PubMed ID: 35750252
[TBL] [Abstract] [Full Text] [Related]
15. A nucleation barrier spring-loads the CBM signalosome for binary activation.
Rodriguez Gama A; Miller T; Lange JJ; Unruh JR; Halfmann R
Elife; 2022 Jun; 11():. PubMed ID: 35727133
[TBL] [Abstract] [Full Text] [Related]
16. bcl10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.
Xia M; David L; Teater M; Gutierrez J; Wang X; Meydan C; Lytle A; Slack GW; Scott DW; Morin RD; Onder O; Elenitoba-Johnson KSJ; Zamponi N; Cerchietti L; Lu T; Philippar U; Fontan L; Wu H; Melnick AM
Cancer Discov; 2022 Aug; 12(8):1922-1941. PubMed ID: 35658124
[TBL] [Abstract] [Full Text] [Related]
17. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Ferreri AJM; Angelillo P; Erbella F; Cattaneo C; Verga L; Lleshi A; Allione B; Ponzoni M; Facchetti F; Pagani C; Foppoli M; Pecciarini L; Sassone M; Steffanoni S; Flospergher E; Rossi G; Spina M; Re A
Blood Adv; 2022 Nov; 6(22):5811-5820. PubMed ID: 35580327
[TBL] [Abstract] [Full Text] [Related]
18. USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.
Wu Y; Gu H; Bao Y; Lin T; Wang Z; Gu D; Shen H; Xian H; Fan Y; Mao R
Cell Biochem Funct; 2022 Jun; 40(4):379-390. PubMed ID: 35411950
[TBL] [Abstract] [Full Text] [Related]
19. CARD11 signaling in regulatory T cell development and function.
Carter NM; Pomerantz JL
Adv Biol Regul; 2022 May; 84():100890. PubMed ID: 35255409
[TBL] [Abstract] [Full Text] [Related]
20. Effects of gestational exposure to bisphenol A on the hepatic transcriptome and lipidome of rat dams: Intergenerational comparison of effects in the offspring.
Nguyen HT; Li L; Eguchi A; Agusa T; Yamamoto K; Kannan K; Kim EY; Iwata H
Sci Total Environ; 2022 Jun; 826():153990. PubMed ID: 35192832
[TBL] [Abstract] [Full Text] [Related]
[Next]
